This map shows the geographic impact of Paul Bowness's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Bowness with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Bowness more than expected).
This network shows the impact of papers produced by Paul Bowness. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Bowness. The network helps show where Paul Bowness may publish in the future.
Co-authorship network of co-authors of Paul Bowness
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Bowness.
A scholar is included among the top collaborators of Paul Bowness based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Paul Bowness. Paul Bowness is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Al‐Mossawi, Hussein, Chris Worth, Patrícia Maria Abreu Machado, et al.. (2021). A first in disease phase 2A trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study). Clinical and Experimental Rheumatology. 39(5). 1161–1161.
Bowness, Paul. (2014). HLA-B27, ANTIGEN PRESENTATION AND ERAP1. Clinical and Experimental Rheumatology. 32. 768–768.1 indexed citations
8.
McHugh, Kirsty, et al.. (2014). WHAT HAVE WE LEARNED ABOUT NON-CLASSICAL FORMS OF HLA-B27 AND ITS ROLE IN THE PATHOGENESIS OF SPONDYLOARTHROPATHIES?. Clinical and Experimental Rheumatology. 32. 815–815.1 indexed citations
9.
Al‐Mossawi, Hussein, et al.. (2013). CHARACTERIZING TYPE 17 IMMUNE RESPONSES IN ANKYLOSING SPONDYLITIS. Lara D. Veeken. 52. 28–29.1 indexed citations
10.
Ridley, Anne J., C. Cohen, Tugce Karaderi, et al.. (2013). Increased IL-23 Receptor Expression Is Observed On KIR3DL2+CD4+T Cells In Ankylosing Spondylitis and Correlates With IL-23R Polymorphisms. Immunology. 140. 140–141.1 indexed citations
11.
Fischer, Román, David C. Trudgian, Cynthia Wright, et al.. (2012). Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. QUT ePrints (Queensland University of Technology).2 indexed citations
12.
Bowness, Paul. (2012). OVERVIEW OF ANKYLOSING SPONDYLITIS GENETICS AND PATHOGENESIS. Lara D. Veeken. 51. 18–18.3 indexed citations
13.
McHugh, Kirsty, et al.. (2010). Factors determining the cell surface expression of a novel HLA-B27 epitope. Immunology. 131. 110–110.1 indexed citations
14.
Chan, Antoni, Simon Kollnberger, Lucy R. Wedderburn, & Paul Bowness. (2005). Expansion and increased survival of natural killer and CD4 T cells expressing the Killer IG-like Receptor KIR3DL2 in spondyloarthritis.. UCL Discovery (University College London). 52.1 indexed citations
Bowness, Paul, et al.. (1992). T-CELL RECEPTOR USAGE OF SYNOVIAL LYMPHOCYTES FROM A PATIENT WITH REACTIVE ARTHRITIS. Lara D. Veeken. 31. 40–40.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.